# MAESTRA 3 (NCT07797283)

> Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07797283
- Phase: PHASE3
- Status: NOT_YET_RECRUITING
- Sponsor: Incyte Corporation
- Conditions: Ovarian Cancer
- Interventions: INCB123667; Bevacizumab; Placebo
- Enrollment: 590
- Primary outcome: Progression-Free Survival (PFS) by BICR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=maestra-3-nct07797283